Skip to main content
VISIT JANSSEN GLOBAL
 
 
 

UK
change location▼

Search
Search

Welcome to Janssen UK

Visit Janssen Global

Home › Media

Media Centre

The News Centre is intended to provide resources for media professionals only. It is not intended for use by healthcare professionals, patients or the general public. To access, please confirm that you are an accredited member of the press. I hereby confirm that I am an accredited member of the press
I Agree Cancel

Press Releases

08, September, 2021

NICE backs Janssen’s Erleada®▼ (apalutamide) for Hormone-Sensitive Metastatic and Hormone-Relapsed Non-Metastatic Prostate Cancer

10, August, 2021

PONVORY®▼ (ponesimod), a Once Daily, Oral Therapy Authorised in Great Britain for the Treatment of Adults with Relapsing Forms of Multiple Sclerosis (RMS) with Active Disease Defined by Clinical or Imaging Features

09, August, 2021

SCOTTISH MEDICINES CONSORTIUM (SMC) ACCEPTS TREMFYA®▼ (GUSELKUMAB), THE FIRST IL-23 p19 INHIBITOR TREATMENT, FOR ACTIVE PSORIATIC ARTHRITIS (PsA)

28, May, 2021

Single-Dose COVID-19 Vaccine Janssen▼ Granted Conditional Marketing Authorisation by the Medicines and Healthcare Products Regulatory Agency (MHRA)

28, May, 2021

NICE RECOMMENDS TREMFYA®▼ (GUSELKUMAB) A FIRST-IN-CLASS TREATMENT FOR ACTIVE PSORIATIC ARTHRITIS (PsA)

29, January, 2021

Johnson & Johnson Announces Single-Shot Janssen COVID-19 Vaccine Candidate Met Primary Endpoints in Interim Analysis of its Phase 3 ENSEMBLE Trial

View more Press Releases

Quick Links

 

FOLLOW US

 

Twitter

Follow us on Twitter